Creative Medical Technology Holdings, Inc. (CELZ): Forward Price-to-Revenue Multiple
Creative Medical Technology is developing diversified regenerative therapy programs for orthopedics and urology, thereby minimizing strategic risks. Proprietary patents on cell lines enable the implementation of non-invasive restoration methods. The forward P/S metric helps assess the investment's margin of safety, where 849.40 reflects the latest value of the metric. However, the commercial impact is limited by a distant clinical trial horizon, and R&D costs have already been priced in by the market.
CELZ (creativemedicaltechnology.com): analytical breakdowns and indicator data
Forward P/S determines market capitalization relative to projected revenue, measuring the premium investors are willing to pay per unit of future sales. The expected P/S valuation on the GURU.Markets platform reflects the revaluation dynamics of Creative Medical Technology (CELZ), whose revenues are currently driven primarily by investment funding for clinical developments and the expansion of its patent portfolio in the field of stem cell therapy.
